[Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir].
Identifieur interne : 000050 ( Main/Exploration ); précédent : 000049; suivant : 000051[Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir].
Auteurs : David Brandariz-Nu Ez [Espagne] ; Marcelo Correas-Sanahuja [Espagne] ; Eva Guarc [Espagne] ; Rafael Pic N [Espagne] ; Bárbara García [Espagne] ; Rocío Gil [Espagne]Source :
- Medicina clinica [ 1578-8989 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Association médicamenteuse (MeSH), Betacoronavirus (MeSH), Facteurs de risque (MeSH), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Interactions médicamenteuses (MeSH), Lopinavir (effets indésirables), Lopinavir (usage thérapeutique), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Ritonavir (effets indésirables), Ritonavir (usage thérapeutique), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Études transversales (MeSH).
- MESH :
- effets indésirables : Antiviraux, Lopinavir, Ritonavir.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Lopinavir, Ritonavir.
- Adulte, Adulte d'âge moyen, Association médicamenteuse, Betacoronavirus, Facteurs de risque, Femelle, Humains, Interactions médicamenteuses, Mâle, Pandémies, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Études transversales.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), Coronavirus Infections (drug therapy), Cross-Sectional Studies (MeSH), Drug Combinations (MeSH), Drug Interactions (MeSH), Female (MeSH), Humans (MeSH), Lopinavir (adverse effects), Lopinavir (therapeutic use), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Risk Factors (MeSH), Ritonavir (adverse effects), Ritonavir (therapeutic use), Treatment Outcome (MeSH).
- MESH :
- chemical , adverse effects : Antiviral Agents, Lopinavir, Ritonavir.
- chemical , therapeutic use : Antiviral Agents, Lopinavir, Ritonavir.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Adult, Aged, Aged, 80 and over, Betacoronavirus, Cross-Sectional Studies, Drug Combinations, Drug Interactions, Female, Humans, Male, Middle Aged, Pandemics, Risk Factors, Treatment Outcome.
Abstract
OBJECTIVES
To determine the prevalence of potential interactions in COVID-19 patients receiving lopinavir/ritonavir (LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r.
SUBJECTS AND METHODS
Cross-sectional and multicenter study with the participation of 2 hospitals. COVID-19 patients over 18 years of age, admitted to hospital and under treatment with LPV/r were included. A screening of potential interactions related to LPV/r and home and hospital medication was carried out. Lexicomp® (Uptodate), HIV-drug interactions and COVID-drug interactions were used as the query database.
RESULTS
361 patients with a mean age of 62.77 ± 14.64 years were included, where 59.6% (n = 215) were men. 62.3% (n = 225) had 1 or more potential interactions and 26, 87% (n = 97) 2 or more. The independent variables associated with presenting ≥1 potential interactions were age (> 65) (OR 1.95; 95% CI 1.06-3.59, P =.033), ICU admission (OR 9.22; CI 95% 1.98-42.93; P =.005), previous respiratory pathology (OR 2.90; 95% CI 1.15-7.36; P =.024), psychiatric (OR 4.14; 95 CI % 1.36-12.61; P =.013), dyslipidemia (OR 3.21; 95% CI 1.63-6.35; P =.001) and the number of drugs prescribed (OR 4.33; 95% CI 2.40-7.81; P =.000).
CONCLUSION
The prevalence of potential interactions in COVD-19 patient undergoing treatment with LPV/r is high, with age (> 65), ICU admission, previous respiratory and psychiatric pathology, dyslipidemia and the number of prescribed drugs acting as risk factors.
DOI: 10.1016/j.medcli.2020.06.026
PubMed: 32718719
PubMed Central: PMC7346810
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir].</title><author><name sortKey="Brandariz Nu Ez, David" sort="Brandariz Nu Ez, David" uniqKey="Brandariz Nu Ez D" first="David" last="Brandariz-Nu Ez">David Brandariz-Nu Ez</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España. Electronic address: vrandariz@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital Quironsalud, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Correas Sanahuja, Marcelo" sort="Correas Sanahuja, Marcelo" uniqKey="Correas Sanahuja M" first="Marcelo" last="Correas-Sanahuja">Marcelo Correas-Sanahuja</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital CIMA, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital CIMA, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Guarc, Eva" sort="Guarc, Eva" uniqKey="Guarc E" first="Eva" last="Guarc">Eva Guarc</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital Quironsalud, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Pic N, Rafael" sort="Pic N, Rafael" uniqKey="Pic N R" first="Rafael" last="Pic N">Rafael Pic N</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital Quironsalud, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Garcia, Barbara" sort="Garcia, Barbara" uniqKey="Garcia B" first="Bárbara" last="García">Bárbara García</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital Quironsalud, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Gil, Rocio" sort="Gil, Rocio" uniqKey="Gil R" first="Rocío" last="Gil">Rocío Gil</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital Quironsalud, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32718719</idno><idno type="pmid">32718719</idno><idno type="doi">10.1016/j.medcli.2020.06.026</idno><idno type="pmc">PMC7346810</idno><idno type="wicri:Area/Main/Corpus">000981</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000981</idno><idno type="wicri:Area/Main/Curation">000981</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000981</idno><idno type="wicri:Area/Main/Exploration">000981</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir].</title><author><name sortKey="Brandariz Nu Ez, David" sort="Brandariz Nu Ez, David" uniqKey="Brandariz Nu Ez D" first="David" last="Brandariz-Nu Ez">David Brandariz-Nu Ez</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España. Electronic address: vrandariz@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital Quironsalud, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Correas Sanahuja, Marcelo" sort="Correas Sanahuja, Marcelo" uniqKey="Correas Sanahuja M" first="Marcelo" last="Correas-Sanahuja">Marcelo Correas-Sanahuja</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital CIMA, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital CIMA, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Guarc, Eva" sort="Guarc, Eva" uniqKey="Guarc E" first="Eva" last="Guarc">Eva Guarc</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital Quironsalud, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Pic N, Rafael" sort="Pic N, Rafael" uniqKey="Pic N R" first="Rafael" last="Pic N">Rafael Pic N</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital Quironsalud, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Garcia, Barbara" sort="Garcia, Barbara" uniqKey="Garcia B" first="Bárbara" last="García">Bárbara García</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital Quironsalud, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Gil, Rocio" sort="Gil, Rocio" uniqKey="Gil R" first="Rocío" last="Gil">Rocío Gil</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Farmacia, Hospital Quironsalud, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></analytic><series><title level="j">Medicina clinica</title><idno type="eISSN">1578-8989</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Cross-Sectional Studies (MeSH)</term><term>Drug Combinations (MeSH)</term><term>Drug Interactions (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Lopinavir (adverse effects)</term><term>Lopinavir (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Risk Factors (MeSH)</term><term>Ritonavir (adverse effects)</term><term>Ritonavir (therapeutic use)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Association médicamenteuse (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>Facteurs de risque (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Interactions médicamenteuses (MeSH)</term><term>Lopinavir (effets indésirables)</term><term>Lopinavir (usage thérapeutique)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Ritonavir (effets indésirables)</term><term>Ritonavir (usage thérapeutique)</term><term>Résultat thérapeutique (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Études transversales (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Betacoronavirus</term><term>Cross-Sectional Studies</term><term>Drug Combinations</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Risk Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association médicamenteuse</term><term>Betacoronavirus</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Mâle</term><term>Pandémies</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études transversales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To determine the prevalence of potential interactions in COVID-19 patients receiving lopinavir/ritonavir (LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r.</p></div><div type="abstract" xml:lang="en"><p><b>SUBJECTS AND METHODS</b></p><p>Cross-sectional and multicenter study with the participation of 2 hospitals. COVID-19 patients over 18 years of age, admitted to hospital and under treatment with LPV/r were included. A screening of potential interactions related to LPV/r and home and hospital medication was carried out. Lexicomp® (Uptodate), HIV-drug interactions and COVID-drug interactions were used as the query database.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>361 patients with a mean age of 62.77 ± 14.64 years were included, where 59.6% (n = 215) were men. 62.3% (n = 225) had 1 or more potential interactions and 26, 87% (n = 97) 2 or more. The independent variables associated with presenting ≥1 potential interactions were age (> 65) (OR 1.95; 95% CI 1.06-3.59, P =.033), ICU admission (OR 9.22; CI 95% 1.98-42.93; P =.005), previous respiratory pathology (OR 2.90; 95% CI 1.15-7.36; P =.024), psychiatric (OR 4.14; 95 CI % 1.36-12.61; P =.013), dyslipidemia (OR 3.21; 95% CI 1.63-6.35; P =.001) and the number of drugs prescribed (OR 4.33; 95% CI 2.40-7.81; P =.000).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>The prevalence of potential interactions in COVD-19 patient undergoing treatment with LPV/r is high, with age (> 65), ICU admission, previous respiratory and psychiatric pathology, dyslipidemia and the number of prescribed drugs acting as risk factors.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32718719</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>155</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>10</Month><Day>09</Day></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>[Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir].</ArticleTitle><Pagination><MedlinePgn>281-287</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0025-7753(20)30450-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2020.06.026</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To determine the prevalence of potential interactions in COVID-19 patients receiving lopinavir/ritonavir (LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r.</AbstractText><AbstractText Label="SUBJECTS AND METHODS">Cross-sectional and multicenter study with the participation of 2 hospitals. COVID-19 patients over 18 years of age, admitted to hospital and under treatment with LPV/r were included. A screening of potential interactions related to LPV/r and home and hospital medication was carried out. Lexicomp® (Uptodate), HIV-drug interactions and COVID-drug interactions were used as the query database.</AbstractText><AbstractText Label="RESULTS">361 patients with a mean age of 62.77 ± 14.64 years were included, where 59.6% (n = 215) were men. 62.3% (n = 225) had 1 or more potential interactions and 26, 87% (n = 97) 2 or more. The independent variables associated with presenting ≥1 potential interactions were age (> 65) (OR 1.95; 95% CI 1.06-3.59, P =.033), ICU admission (OR 9.22; CI 95% 1.98-42.93; P =.005), previous respiratory pathology (OR 2.90; 95% CI 1.15-7.36; P =.024), psychiatric (OR 4.14; 95 CI % 1.36-12.61; P =.013), dyslipidemia (OR 3.21; 95% CI 1.63-6.35; P =.001) and the number of drugs prescribed (OR 4.33; 95% CI 2.40-7.81; P =.000).</AbstractText><AbstractText Label="CONCLUSION">The prevalence of potential interactions in COVD-19 patient undergoing treatment with LPV/r is high, with age (> 65), ICU admission, previous respiratory and psychiatric pathology, dyslipidemia and the number of prescribed drugs acting as risk factors.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier España, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brandariz-Nuñez</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España. Electronic address: vrandariz@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Correas-Sanahuja</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Farmacia, Hospital CIMA, Barcelona, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guarc</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Picón</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García</LastName><ForeName>Bárbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>Rocío</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><VernacularTitle>Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID 19</Keyword><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Inhibidor de la proteasa</Keyword><Keyword MajorTopicYN="Y">Interacciones medicamentosas potenciales</Keyword><Keyword MajorTopicYN="Y">Lopinavir/ritonavir</Keyword><Keyword MajorTopicYN="Y">Potential drug-drug interactions</Keyword><Keyword MajorTopicYN="Y">Protease inhibitor</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32718719</ArticleId><ArticleId IdType="pii">S0025-7753(20)30450-4</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2020.06.026</ArticleId><ArticleId IdType="pmc">PMC7346810</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Brandariz Nu Ez, David" sort="Brandariz Nu Ez, David" uniqKey="Brandariz Nu Ez D" first="David" last="Brandariz-Nu Ez">David Brandariz-Nu Ez</name></region><name sortKey="Correas Sanahuja, Marcelo" sort="Correas Sanahuja, Marcelo" uniqKey="Correas Sanahuja M" first="Marcelo" last="Correas-Sanahuja">Marcelo Correas-Sanahuja</name><name sortKey="Garcia, Barbara" sort="Garcia, Barbara" uniqKey="Garcia B" first="Bárbara" last="García">Bárbara García</name><name sortKey="Gil, Rocio" sort="Gil, Rocio" uniqKey="Gil R" first="Rocío" last="Gil">Rocío Gil</name><name sortKey="Guarc, Eva" sort="Guarc, Eva" uniqKey="Guarc E" first="Eva" last="Guarc">Eva Guarc</name><name sortKey="Pic N, Rafael" sort="Pic N, Rafael" uniqKey="Pic N R" first="Rafael" last="Pic N">Rafael Pic N</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000050 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000050 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32718719
|texte= [Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32718719" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |